(Q42747885)

6 November 2017

New multidisciplinary prostate bone metastases clinic: first of its kind in Canada (English)

1 reference

6 November 2017

0 references

P Goh

1

1 reference

6 November 2017

K Harris

2

1 reference

6 November 2017

J Napolskikh

3

1 reference

6 November 2017

E Chow

4

1 reference

6 November 2017

E Sinclair

5

1 reference

6 November 2017

U Emmenegger

6

1 reference

6 November 2017

S Lemon

7

1 reference

6 November 2017

A Yee

8

1 reference

6 November 2017

L Wynnychuk

9

1 reference

6 November 2017

J Myers

10

1 reference

6 November 2017

C Danjoux

11

1 reference

6 November 2017

Y Ko

12

1 reference

6 November 2017

Bone Metastases Site Group

13

1 reference

6 November 2017

1 February 2007

1 reference

6 November 2017

1 reference

6 November 2017

14

1 reference

6 November 2017

1

1 reference

6 November 2017

9-12

1 reference

Creative Commons Attribution 4.0 International

6 November 2017

start time

1 February 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Treatment options in hormone-refractory metastatic prostate carcinoma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

The role of bisphosphonates in hormone-refractory prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

The role of bisphosphonates in breast and prostate cancers

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Advances in the use of bisphosphonates in the prostate cancer setting

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Bisphosphonates in the management of metastatic prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Mechanisms involved in the metastasis of cancer to bone

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Metastatic bone disease: clinical and therapeutic aspects

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Management of acute hypercalcemia

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Chemotherapy for patients with hormone-refractory prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Spinal cord compression in metastatic prostate cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1891195

16 August 2018

Identifiers

DOI

10.3747/CO.2007.101

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

17576458

1 reference